Cargando…
Alpha-Synuclein-Specific Naturally Occurring Antibodies Inhibit Aggregation In Vitro and In Vivo
Parkinson’s disease (PD) is associated with motor and non-motor symptoms and characterized by aggregates of alpha-synuclein (αSyn). Naturally occurring antibodies (nAbs) are part of the innate immune system, produced without prior contact to their specific antigen, and polyreactive. The abundance of...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946620/ https://www.ncbi.nlm.nih.gov/pubmed/35327661 http://dx.doi.org/10.3390/biom12030469 |
_version_ | 1784674237672325120 |
---|---|
author | Braczynski, Anne K. Sevenich, Marc Gering, Ian Kupreichyk, Tatsiana Agerschou, Emil D. Kronimus, Yannick Habib, Pardes Stoldt, Matthias Willbold, Dieter Schulz, Jörg B. Bach, Jan-Philipp Falkenburger, Björn H. Hoyer, Wolfgang |
author_facet | Braczynski, Anne K. Sevenich, Marc Gering, Ian Kupreichyk, Tatsiana Agerschou, Emil D. Kronimus, Yannick Habib, Pardes Stoldt, Matthias Willbold, Dieter Schulz, Jörg B. Bach, Jan-Philipp Falkenburger, Björn H. Hoyer, Wolfgang |
author_sort | Braczynski, Anne K. |
collection | PubMed |
description | Parkinson’s disease (PD) is associated with motor and non-motor symptoms and characterized by aggregates of alpha-synuclein (αSyn). Naturally occurring antibodies (nAbs) are part of the innate immune system, produced without prior contact to their specific antigen, and polyreactive. The abundance of nAbs against αSyn is altered in patients with PD. In this work, we biophysically characterized nAbs against αSyn (nAbs-αSyn) and determined their biological effects. nAbs-αSyn were isolated from commercial intravenous immunoglobulins using column affinity purification. Biophysical properties were characterized using a battery of established in vitro assays. Biological effects were characterized in HEK293T cells transiently transfected with fluorescently tagged αSyn. Specific binding of nAbs-αSyn to monomeric αSyn was demonstrated by Dot blot, ELISA, and Surface Plasmon Resonance. nAbs-αSyn did not affect viability of HEK293T cells as reported by Cell Titer Blue and LDH Assays. nAbs-αSyn inhibited fibrillation of αSyn reported by the Thioflavin T aggregation assay. Altered fibril formation was confirmed with atomic force microscopy. In cells transfected with EGFP-tagged αSyn we observed reduced formation of aggresomes, perinuclear accumulations of αSyn aggregates. The results demonstrate that serum of healthy individuals contains nAbs that specifically bind αSyn and inhibit aggregation of αSyn in vitro. The addition of nAbs-αSyn to cultured cells affects intracellular αSyn aggregates. These findings help understanding the role of the innate immune systems for the pathogenesis of PD and suggest that systemic αSyn binding agents could potentially affect neuronal αSyn pathology. |
format | Online Article Text |
id | pubmed-8946620 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89466202022-03-25 Alpha-Synuclein-Specific Naturally Occurring Antibodies Inhibit Aggregation In Vitro and In Vivo Braczynski, Anne K. Sevenich, Marc Gering, Ian Kupreichyk, Tatsiana Agerschou, Emil D. Kronimus, Yannick Habib, Pardes Stoldt, Matthias Willbold, Dieter Schulz, Jörg B. Bach, Jan-Philipp Falkenburger, Björn H. Hoyer, Wolfgang Biomolecules Article Parkinson’s disease (PD) is associated with motor and non-motor symptoms and characterized by aggregates of alpha-synuclein (αSyn). Naturally occurring antibodies (nAbs) are part of the innate immune system, produced without prior contact to their specific antigen, and polyreactive. The abundance of nAbs against αSyn is altered in patients with PD. In this work, we biophysically characterized nAbs against αSyn (nAbs-αSyn) and determined their biological effects. nAbs-αSyn were isolated from commercial intravenous immunoglobulins using column affinity purification. Biophysical properties were characterized using a battery of established in vitro assays. Biological effects were characterized in HEK293T cells transiently transfected with fluorescently tagged αSyn. Specific binding of nAbs-αSyn to monomeric αSyn was demonstrated by Dot blot, ELISA, and Surface Plasmon Resonance. nAbs-αSyn did not affect viability of HEK293T cells as reported by Cell Titer Blue and LDH Assays. nAbs-αSyn inhibited fibrillation of αSyn reported by the Thioflavin T aggregation assay. Altered fibril formation was confirmed with atomic force microscopy. In cells transfected with EGFP-tagged αSyn we observed reduced formation of aggresomes, perinuclear accumulations of αSyn aggregates. The results demonstrate that serum of healthy individuals contains nAbs that specifically bind αSyn and inhibit aggregation of αSyn in vitro. The addition of nAbs-αSyn to cultured cells affects intracellular αSyn aggregates. These findings help understanding the role of the innate immune systems for the pathogenesis of PD and suggest that systemic αSyn binding agents could potentially affect neuronal αSyn pathology. MDPI 2022-03-18 /pmc/articles/PMC8946620/ /pubmed/35327661 http://dx.doi.org/10.3390/biom12030469 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Braczynski, Anne K. Sevenich, Marc Gering, Ian Kupreichyk, Tatsiana Agerschou, Emil D. Kronimus, Yannick Habib, Pardes Stoldt, Matthias Willbold, Dieter Schulz, Jörg B. Bach, Jan-Philipp Falkenburger, Björn H. Hoyer, Wolfgang Alpha-Synuclein-Specific Naturally Occurring Antibodies Inhibit Aggregation In Vitro and In Vivo |
title | Alpha-Synuclein-Specific Naturally Occurring Antibodies Inhibit Aggregation In Vitro and In Vivo |
title_full | Alpha-Synuclein-Specific Naturally Occurring Antibodies Inhibit Aggregation In Vitro and In Vivo |
title_fullStr | Alpha-Synuclein-Specific Naturally Occurring Antibodies Inhibit Aggregation In Vitro and In Vivo |
title_full_unstemmed | Alpha-Synuclein-Specific Naturally Occurring Antibodies Inhibit Aggregation In Vitro and In Vivo |
title_short | Alpha-Synuclein-Specific Naturally Occurring Antibodies Inhibit Aggregation In Vitro and In Vivo |
title_sort | alpha-synuclein-specific naturally occurring antibodies inhibit aggregation in vitro and in vivo |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946620/ https://www.ncbi.nlm.nih.gov/pubmed/35327661 http://dx.doi.org/10.3390/biom12030469 |
work_keys_str_mv | AT braczynskiannek alphasynucleinspecificnaturallyoccurringantibodiesinhibitaggregationinvitroandinvivo AT sevenichmarc alphasynucleinspecificnaturallyoccurringantibodiesinhibitaggregationinvitroandinvivo AT geringian alphasynucleinspecificnaturallyoccurringantibodiesinhibitaggregationinvitroandinvivo AT kupreichyktatsiana alphasynucleinspecificnaturallyoccurringantibodiesinhibitaggregationinvitroandinvivo AT agerschouemild alphasynucleinspecificnaturallyoccurringantibodiesinhibitaggregationinvitroandinvivo AT kronimusyannick alphasynucleinspecificnaturallyoccurringantibodiesinhibitaggregationinvitroandinvivo AT habibpardes alphasynucleinspecificnaturallyoccurringantibodiesinhibitaggregationinvitroandinvivo AT stoldtmatthias alphasynucleinspecificnaturallyoccurringantibodiesinhibitaggregationinvitroandinvivo AT willbolddieter alphasynucleinspecificnaturallyoccurringantibodiesinhibitaggregationinvitroandinvivo AT schulzjorgb alphasynucleinspecificnaturallyoccurringantibodiesinhibitaggregationinvitroandinvivo AT bachjanphilipp alphasynucleinspecificnaturallyoccurringantibodiesinhibitaggregationinvitroandinvivo AT falkenburgerbjornh alphasynucleinspecificnaturallyoccurringantibodiesinhibitaggregationinvitroandinvivo AT hoyerwolfgang alphasynucleinspecificnaturallyoccurringantibodiesinhibitaggregationinvitroandinvivo |